A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Titel:
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Auteur:
Rosenbaum, Evan Chugh, Rashmi Ryan, Christopher W. Agulnik, Mark Milhem, Mohammed M. George, Suzanne Jones, Robin L. Chmielowski, Bartosz Van Tine, Brian A. Tawbi, Hussein Elias, Anthony D. Read, William L. Budd, G. Thomas Qin, Li-Xuan Rodler, Eve T. Hirman, Joe Weiden, Paul Bennett, Cathryn M. Livingston, Philip O. Ragupathi, Govind Hansen, David D'Angelo, Sandra P. Tap, William D. Schwartz, Gary K. Maki, Robert G. Carvajal, Richard D.